Molecular Biological Approach towards Efficient Radioimmunotherapy

高效放射免疫治疗的分子生物学方法

基本信息

  • 批准号:
    07671027
  • 负责人:
  • 金额:
    $ 1.47万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1995
  • 资助国家:
    日本
  • 起止时间:
    1995 至 1996
  • 项目状态:
    已结题

项目摘要

The aim of this study is to evaluate the tumor cells treated with radiolabeled monoclonal antibodies from the molecular biological point of view. The effects of dose of radiolabeled antibodies and fractionation were investigated to get the following results.1. Human gastric cancer cells producing CEA were incubated with I-131-labeled anti-CEA monoclonal antibody :(1) No apoptosis was observed in tumor cells.(2) Cytotoxicity was dose dependent, and repeated incubation caused higher toxicity than one incubations.2. Murine leukemia cells were incubated with I-131-labeled monoclonal antibody which was reactive with cell surface antigen :(1) Apoptosis was observed in tumor cells.(2) Apoptosis was observed in tumor cells which were incubated with I-131-labeled irrelevant antibody or I-131 ; indicating that apoptosis is not specific for radiolabeled antibodies.3. Athymic nude mice bearing human gastric cancer xenografts were injected with I-131-labeled anti-CEA monoclonal antibody :(1) No apoptosis was observed in tumor cells by any dose of I-131-labeled antibody.(2) Necrosis was observed in xenografts when mice were injected with I-131-labeled antibody intratumorally. Fractionation reduced the uptake of I-131 in the tumors.4. Hetero, athymic nude, or SCID mice bearing leukemia cells intraperitoneally were injected with I-131-labeled antibody :(1) Apoptosis was observed in leukemia cells in any mice.(2) Apoptosis was observed in only hetero mice by the low dose of I-131-antibody. High does of I-131-labeled antibody caused the radiation damage in SCID mice ; indicating that apoptosis occurred through the immunogenic pathways.5.The study suggested that :(1) Apoptosis would not be mainly involved in solid tumors by radioimmunotherapy.(2) Apoptosis is an important factors in hematological tumors in conjunction with the immunogenecity from the host when it is treated by radioimmunotherapy.
本研究的目的是从分子生物学的角度评价放射性标记的单克隆抗体处理的肿瘤细胞。研究了放射性标记抗体的剂量和分级的影响,得到以下结果.用~(131)I标记的抗CEA单克隆抗体孵育产生CEA的人胃癌细胞:(1)未观察到肿瘤细胞凋亡。(2)细胞毒性呈剂量依赖性,重复孵育的细胞毒性高于单次孵育.用~(131)I标记的单克隆抗体与小鼠白血病细胞共孵育:(1)肿瘤细胞出现凋亡。(2)在与I-131标记的无关抗体或I-131孵育的肿瘤细胞中观察到凋亡,表明凋亡对放射性标记的抗体没有特异性.用~(131)I标记的抗CEA单克隆抗体注射荷人胃癌裸鼠:(1)任何剂量的~(131)I标记抗体均未引起肿瘤细胞凋亡。(2)当小鼠瘤内注射I-131标记的抗体时,在异种移植物中观察到坏死。分级降低肿瘤对I-131的摄取.用~(131)I标记的抗体腹腔注射荷白血病细胞的荷瘤小鼠、裸鼠和SCID小鼠,结果发现:(1)所有小鼠的白血病细胞均出现凋亡。(2)低剂量的I-131-抗体仅在异种小鼠中观察到细胞凋亡。高剂量的I-131标记抗体可引起SCID小鼠的放射损伤,表明细胞凋亡是通过免疫原性途径发生的。(2)细胞凋亡是血液肿瘤放射免疫治疗中与宿主免疫原性相关的重要因素。

项目成果

期刊论文数量(26)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Kayoko Nakamura: "Effect of interferon-minipellet on radiolabelled antibody targeting." European Journal of Nuclear Medicine. 22 (8). 839 (1995)
Kayoko Nakamura:“干扰素小丸对放射性标记抗体靶向的影响。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kayoko Nakamura: "Distribution and Pharmacokinetics of ^<111>In-DTPA-IgG in Healthy Human Subjects" RADIOISOTOPES. 44. 303-309 (1995)
Kayoko Nakamura:“^<111>In-DTPA-IgG 在健康人类受试者中的分布和药代动力学”放射性同位素。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
中村佳代子: "酵素阻害剤がヨード標識抗体の生体内分布に及ぼす影響" 免疫・腫瘍核医学. 10. 29-31 (1995)
Kayoko Nakamura:“酶抑制剂对碘标记抗体生物分布的影响”免疫学/肿瘤核医学。10. 29-31 (1995)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kayoko Nakamura: "Distribution and pharmacokinetics of In-111-DTPA-IgG in healthy human subjects." RADIOISOTOPES. 44 (2). 303-309 (1995)
Kayoko Nakamura:“In-111-DTPA-IgG 在健康人类受试者中的分布和药代动力学。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
中村佳代子: "^<99m>Tc-MIBI集積と多剤耐性" RADIOISOTOPES. 45(10). 661-662 (1996)
Kayoko Nakamura:“^<99m>Tc-MIBI 积累和多药耐药性”RADIOISOTOPES 45(10) (1996)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NAKAMURA Kayoko其他文献

NAKAMURA Kayoko的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NAKAMURA Kayoko', 18)}}的其他基金

Optical and Nuclear Imaging of Tumor-related genes
肿瘤相关基因的光学和核成像
  • 批准号:
    19591434
  • 财政年份:
    2007
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Gene Imaging for Studying Pharmacokinetics of Gene in Vivo at the Real Time
基因成像用于实时研究基因体内药代动力学
  • 批准号:
    16591225
  • 财政年份:
    2004
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
In Vivo Diagnosis of Gene Localization and Expression by Nuclear Medicine Modality
通过核医学方式进行基因定位和表达的体内诊断
  • 批准号:
    13670965
  • 财政年份:
    2001
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of Nuclear Medicine Modality for Selecting Cancer Therapy and for Predicting Therapeutic Efficacy from Molecular Biological Points of View
从分子生物学角度选择癌症治疗和预测治疗效果的核医学模式的发展
  • 批准号:
    11670912
  • 财政年份:
    1999
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Modification of Multidrug Resistance by Magnetic Exposure Indicated from the Point of View of Nuclear Medicine
从核医学的角度表明磁暴露对多药耐药性的改变
  • 批准号:
    09670954
  • 财政年份:
    1997
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Pharmacokinetic Study of Targeting Tumors with Radio-and Drug-conjugated Monoclonal Antibody
放射性和药物结合的单克隆抗体靶向肿瘤的药代动力学研究
  • 批准号:
    05670785
  • 财政年份:
    1993
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
Biochemical and Immunological Characterization of Tumors by Immunoscintigraphy
通过免疫闪烁扫描法对肿瘤进行生化和免疫学表征
  • 批准号:
    63570496
  • 财政年份:
    1988
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

HARNESSING IN VIVO CLICK CHEMISTRY FOR 211AT-BASED PRETARGETED RADIOIMMUNOTHERAPY
利用体内点击化学进行基于 211AT 的预定位放射免疫治疗
  • 批准号:
    10679160
  • 财政年份:
    2023
  • 资助金额:
    $ 1.47万
  • 项目类别:
Targeted mimetic nanovesicles for radioimmunotherapy
用于放射免疫治疗的靶向模拟纳米囊泡
  • 批准号:
    574914-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 1.47万
  • 项目类别:
    University Undergraduate Student Research Awards
Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted Radioimmunotherapy
碱基编辑造血干细胞和祖细胞可安全使用高效 CD33 靶向放射免疫疗法
  • 批准号:
    10346735
  • 财政年份:
    2022
  • 资助金额:
    $ 1.47万
  • 项目类别:
CD117-Targeted Radioimmunotherapy with Astatine-211 for Acute Myeloid Leukemia and Myelodysplastic Syndrome
CD117 靶向放射免疫治疗砹 211 治疗急性髓系白血病和骨髓增生异常综合征
  • 批准号:
    10670383
  • 财政年份:
    2022
  • 资助金额:
    $ 1.47万
  • 项目类别:
Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted Radioimmunotherapy
碱基编辑造血干细胞和祖细胞可安全使用高效 CD33 靶向放射免疫疗法
  • 批准号:
    10647646
  • 财政年份:
    2022
  • 资助金额:
    $ 1.47万
  • 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
  • 批准号:
    10435886
  • 财政年份:
    2022
  • 资助金额:
    $ 1.47万
  • 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
  • 批准号:
    10576955
  • 财政年份:
    2022
  • 资助金额:
    $ 1.47万
  • 项目类别:
Proof-of-concept Study for Podoplanin-targeted Radioimmunotherapy for Glioblastoma as a New Therapeutic Option
Podoplanin 靶向放射免疫疗法作为胶质母细胞瘤新治疗选择的概念验证研究
  • 批准号:
    22K15871
  • 财政年份:
    2022
  • 资助金额:
    $ 1.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
原位放射免疫疗法可最大限度地发挥传统 1 型树突状细胞对抗非 T 细胞炎症肿瘤的作用
  • 批准号:
    10297983
  • 财政年份:
    2021
  • 资助金额:
    $ 1.47万
  • 项目类别:
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
原位放射免疫疗法可最大限度地发挥传统 1 型树突状细胞对抗非 T 细胞炎症肿瘤的作用
  • 批准号:
    10600657
  • 财政年份:
    2021
  • 资助金额:
    $ 1.47万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了